Biophytis 관리

관리 기준 확인 4/4

Biophytis CEO는 Stanislas Veillet, May2015 에 임명되었습니다 의 임기는 9.5 년입니다. 총 연간 보상은 € 349.00K, 71.6% 로 구성됩니다. 71.6% 급여 및 28.4% 보너스(회사 주식 및 옵션 포함). 는 $ 14.81K 가치에 해당하는 회사 주식의 0.9% 직접 소유합니다. 14.81K. 경영진과 이사회의 평균 재임 기간은 각각 5.1 년과 5.2 년입니다.

주요 정보

Stanislas Veillet

최고 경영자

€349.0k

총 보상

CEO 급여 비율	71.6%
CEO 임기	9.5yrs
CEO 소유권	0.9%
경영진 평균 재임 기간	5.1yrs
이사회 평균 재임 기간	5.2yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Stanislas Veillet 의 보수는 Biophytis 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Jun 30 2024	n/a	n/a	-€15m
Mar 31 2024	n/a	n/a	-€16m
Dec 31 2023	€349k	€250k	-€17m
Sep 30 2023	n/a	n/a	-€18m
Jun 30 2023	n/a	n/a	-€20m
Mar 31 2023	n/a	n/a	-€22m
Dec 31 2022	€428k	€250k	-€24m
Sep 30 2022	n/a	n/a	-€27m
Jun 30 2022	n/a	n/a	-€30m
Mar 31 2022	n/a	n/a	-€31m
Dec 31 2021	€460k	€250k	-€31m
Sep 30 2021	n/a	n/a	-€28m
Jun 30 2021	n/a	n/a	-€25m
Mar 31 2021	n/a	n/a	-€25m
Dec 31 2020	€374k	€250k	-€26m
Sep 30 2020	n/a	n/a	-€24m
Jun 30 2020	n/a	n/a	-€22m
Mar 31 2020	n/a	n/a	-€22m
Dec 31 2019	€310k	€250k	-€19m
Sep 30 2019	n/a	n/a	-€19m
Jun 30 2019	n/a	n/a	-€18m
Mar 31 2019	n/a	n/a	-€15m
Dec 31 2018	€295k	€225k	-€14m
Sep 30 2018	n/a	n/a	-€13m
Jun 30 2018	n/a	n/a	-€12m
Mar 31 2018	n/a	n/a	-€12m
Dec 31 2017	€447k	€150k	-€11m

보상 대 시장: Stanislas 의 총 보상 ($USD 363.43K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 649.63K ).

보상과 수익: Stanislas 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Stanislas Veillet (59 yo)

9.5yrs

테뉴어

€349,000

보상

Mr. Stanislas Veillet, Ph D., serves as Chairman of the Board and Chief Executive Officer of Biophytis SA since May 22, 2015. Mr. Veillet is the Co-founder of Biophytis (created in 2006) and served as its...

리더십 팀

이름	위치	테뉴어	보상	소유권
Stanislas Veillet	Chairman of the Board & CEO	9.5yrs	€349.00k	0.90% $ 14.8k
Waly Dioh	Chief Clinical Operating Officer	5.1yrs	데이터 없음	0.0060% $ 99.1
Pierre Dilda	Chief Scientific Officer	5.1yrs	데이터 없음	0.0032% $ 51.9
Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	5.2yrs	데이터 없음	데이터 없음
Rob van Maanen	Chief Medical Officer	3.2yrs	데이터 없음	0% $ 0
Edouard Bieth	Chief Business Officer	1.2yrs	데이터 없음	데이터 없음
Chiara Baccelli	Chief Pharmaceutical Operations Officer & Quality Assurance Director	1.8yrs	데이터 없음	0% $ 0
_ Teylan	Financial Controller	no data	데이터 없음	데이터 없음

5.1yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: BPTS.Y 의 관리팀은 노련하고 경험 (평균 재직 기간 5.1 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Stanislas Veillet	Chairman of the Board & CEO	9.5yrs	€349.00k	0.90% $ 14.8k
Rene Lafont	Scientific Advisor & Member of Scientific Advisory Board	5.2yrs	데이터 없음	데이터 없음
Claude Allary	Independent Director	3.3yrs	€25.00k	0% $ 0
Jose-Alain Sahel	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Thomas Voit	Member of Scientific Advisory Board	7.1yrs	데이터 없음	데이터 없음
Roger Fielding	Member of Scientific Advisory Board	8.5yrs	데이터 없음	데이터 없음
Jean Mariani	Chairman of Scientific Advisory Board & Director	8.6yrs	€25.00k	0% $ 0
Nadine Coulm	Independent Director	9.5yrs	€25.00k	0.000060% $ 1.0
Yann Meunier	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Bernard Levy	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Dennis Villareal	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Francisco Guarner	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음

5.2yrs

평균 재임 기간

69yo

평균 연령

경험이 풍부한 이사회: BPTS.Y 의 이사회는 경험(평균 재직 기간 5.2 년)으로 간주됩니다.

Biophytis 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A., Annual General Meeting, Mar 18, 2024

Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board

Biophytis S.A. Announces Executive Changes

Biophytis S.A., Annual General Meeting, Jun 16, 2023

Recent updates

Biophytis SA Obtains IND Approval from the FDA to Start Its Phase 2 Oba Study in Obesity

Biophytis S.A., Annual General Meeting, Jun 24, 2024

Biophytis SA Announces the Design of its Phase 2 OBA Clinical Study in Obesity

Biophytis S.A.(OTCPK:BPTS.Y) dropped from NASDAQ Composite Index

Biophytis SA Announces Formation of New Scientific Advisory Board for Its Phase 2 OBA Clinical Study in Obesity

Biophytis SA Launches OBA Phase 2 Clinical Study in Obesity with BIO101 (20-Hydroxyecdysone)

Biophytis S.A., Annual General Meeting, Mar 18, 2024

Biophytis S.A. Announces the Publication of the Results of its COVA Phase 2-3 Study in eClinicalMedicine, Part of The Lancet

Biophytis S.A. and the University of Li Ge Explore the Potential of Sarconeos (BIO101) in the Treatment of Viral Respiratory Diseases

Biophytis S.A. Appoints Yann Meunier and Bernard L vy to its Scientific Advisory Board

Biophytis Receives Notice of Delisting from Nasdaq and Announces It Will Request A Hearing Before the Nasdaq Hearings Panel

Biophytis S.A. Provides an Update on the Progress of its R&D Projects over the 1St Half of the Year and the Last Few Months

Biophytis SA Provides Update on its Early Access Programs for Sarconeos (BIO101) in Treatment of Severe Forms of COVID-19

Biophytis SA Receives Response from the French National Authority for Health to Request for Early Access Authorization in France for Patients Suffering from Severe Forms of COVID-19

Biophytis S.A. Announces Executive Changes

Biophytis Obtains Fda Authorization to Initiate the Sara-31 Phase 3 Study in Sarcopenia

Biophytis SA Announces Next Regulatory Steps in Europe and the United States for its COVA Project

Biophytis SA Receives Positive Opinion for its SARA-31 Phase 3 Study in Sarcopenia in Europe

Biophytis S.A. Files for a Pre-Submission Meeting with the FDA for an Emergency Use Authorization of Sarconeos (BIO101) for the Treatment of COVID-19

Biophytis and Seqens Sign A Partnership to Produce Sarconeos (Bio101) Active Compound

Biophytis SA Filed with the FDA for Authorization to Initiate SARA-31 Phase 3 Study in Sarcopenia

Biophytis SA Reports Clinical Results for Sarconeos (BIO101) in Sarcopenia Treatment at the 16th SCWD International Congress

Biophytis S.A., Annual General Meeting, Jun 16, 2023

Biophytis S.A. has completed a Follow-on Equity Offering in the amount of €2.302535 million.

Biophytis SA Files for Pre-Submission Meeting Request with the European Medicine Agency (EMA) to Discuss Filing for Conditional Marketing Authorisation (CMA) in Europe

Biophytis Announces Positive Final Results of the Phase 2-3 COVA Study with Sarconeos (BIO101) in Severe COVID-19

Biophytis S.A. Judgment of the Paris Court of Appeal of 17 January 2023 in the Case Between Biophytis and Negma Group Ltd

Biophytis to Take Appropriate Measures After Receiving Nasdaq Deficiency Notice

Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19

Biophytis Announces Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

Biophytis S.A. Announces Promising Top Line Results of Its Phase 2-3 Cova Clinical Study in COVID-19-Related Respiratory Failure

Biophytis SA to Update on the Development of Sarconeos (BIO101) in Covid-19 at 4th Annual Longevity Therapeutics Summit

Biophytis Presents the Development of Sarconeos in Phase 3 for the Treatment of Sarcopenia At the 15th SCWD International Congress

Biophytis Presents Preclinical Efficacy Data for Sarconeos (BIO101) in Spinal Muscular Atrophy (SMA), A Rare Neuromuscular Disease

Biophytis SA, Annual General Meeting, Jun 03, 2022

Biophytis SA Announces Chief Financial Officer Changes

Biophytis Sa Receives Approval from the ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patients Through an Expanded Access Program

Biophytis SA to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3

Biophytis to Present Full Results from the Sara-INT Phase 2B Trial of Sarconeos in Sarcopenia At the 11Th Annual International Conference

Biophytis SA Announces DMC Second Interim Analysis Efficacy Results in the Promising Zone Allowing Continuation of Phase 2/3 Cova Study with Sarconeos (Bio101) in Covid-19

Biophytis SA Receives Favorable Recommendation from Data Monitoring Committee Based on Safety Analysis of Sarconeos (BIO101) to Continue Patient Recruitment in the Cova Study in COVID-19

Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021

Biophytis SA to Release Topline Results for SARA-INT Phase 2 Study in August 2021

Biophytis SA Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study

BIOPHYTIS Completes Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the Second Interim Analysis

Biophytis Gives Operational Perspectives on its Sarconeos (BIO101) Ahead of its Upcoming AGM on April 26, 2021

Biophytis SA, Annual General Meeting, Apr 26, 2021

Biophytis Sa Announces That Patient Recruitment Will Begin in France and Belgium for Part 2 of Its Cova Study Assessing Sarconeos

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령